CJC-1295 (no DAC) + Ipamorelin is a research-only combination of two different peptide classes that both stimulate the release of growth hormone (GH) from the pituitary:
1️⃣ CJC-1295 (without DAC)
-
A short-acting analogue of growth hormone–releasing hormone (GHRH).
-
Half-life is only ~30 min, so it gives a quick “signal” to release GH.
2️⃣ Ipamorelin
-
A growth hormone secretagogue / ghrelin receptor agonist (“GHRP”).
-
Mimics the hunger-hormone ghrelin and adds a second signal for GH release.
💡 Why they’re paired in research:
Their mechanisms complement each other — CJC provides the GHRH trigger, Ipamorelin primes the ghrelin receptor — producing a larger pulse of endogenous GH than either alone. The “no DAC” version of CJC is chosen because its short half-life lines up with Ipamorelin’s, so the pulse is brief rather than prolonged.
🔬 Evidence status:
-
Data come mostly from small or pre-clinical studies on GH deficiency, recovery, or body-composition changes.
-
There are no large randomized clinical trials proving effectiveness or long-term safety in healthy adults.
-
Neither peptide (alone or together) is approved by the FDA, EMA, or other regulators for anti-aging, fat loss, or fitness.